BM
BMEA
Biomea Fusion, Inc.
$1.38
+3.38%
$96.2M
No data for this timeframe.
Vol
Market Cap$96.2M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders7 funds
Inst. Value$16.2M
Inst. Activity1 buys / 1 sells
Reddit Sentiment50° Neutral
SEC Reports4
Press Releases3
Recent Activity
May 19, 2026
short_volume
Short Volume: BMEA — 55.7% short (0.3M / 0.5M)
Short: 292,217 | Exempt: 10 | TRF Vol: 524,496 | Short Ratio: 55.7% | Off-exchange volume (dark pool
May 11, 2026
SEC
Biomea Fusion reported Q1 2026 net loss of $12.4M ($0.17/share), narrower than the $29.3M loss ($0.80/share) in Q1 2025,
8-K — Impact 4/10
May 11, 2026
SEC
Biomea Fusion reported Q1 2026 net loss of $12.4M ($0.17/share), significantly narrower than the $29.3M loss in Q1 2025,
PRESS-RELEASE — Impact 5/10
Apr 28, 2026
SEC
Biomea Fusion reported positive 52-week Phase 2 COVALENT-112 topline data for icovamenib in type 1 diabetes (T1D), showi
8-K — Impact 7/10
Apr 1, 2026
Insider
Hitchcock Michael J.M. sold 667,477 shares
Interim CEO @ $0.00 ($0.00)
Apr 1, 2026
Insider
Erdtmann Rainer M sold 452,512 shares
See Remarks @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — ADD
2,968,041 shares ($3.7M)
Inst.
BANK OF AMERICA CORP — NEAR_EXIT
1,307 shares ($1.6K)
Price Targets
$7.29
+429.9% upside
Strong Buy
Current $1.38
Low $4.00
Median $7.00
High $10.00
7 analysts
$4.00
$10.00
Analyst Ratings
5Strong Buy
6Buy
1Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 5, 2026 | Citizens | INITIATE | Market Outperform |
| Apr 28, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Apr 8, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 27, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 25, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.17 ▼ -107.9% | $-0.24 — $-0.10 | 66% YoY | 3 |
| Next Q | $-0.21 ▼ -1127.8% | $-0.34 — $-0.10 | 13% YoY | 3 |
| Current FY | $-0.90 ▲ +8.0% | $-1.27 — $-0.48 | 41% YoY | 5 |
| Next FY | $-1.05 ▲ +0.6% | $-1.40 — $-0.86 | -17% YoY | 5 |
Latest Reports
NEUTRAL
8-K
4/10
Biomea Fusion reported Q1 2026 net loss of $12.4M ($0.17/share), narrower than the $29.3M loss ($0.80/share) in Q1 2025,
May 11, 2026
NEUTRAL
PRESS-RELEASE
5/10
Biomea Fusion reported Q1 2026 net loss of $12.4M ($0.17/share), significantly narrower than the $29.3M loss in Q1 2025,
May 11, 2026
BULLISH
Press
6/10
Biomea Fusion reported positive 52-week Phase 2 data for icovamenib in type 1 diabetes, showing a 52% increase in C-pept
Apr 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $10.9M | ADD |
| VANGUARD GROUP INC | $3.7M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $593.5K | NEW |
| TWO SIGMA INVESTMENTS, LP | $525.1K | ADD |
| MORGAN STANLEY | $462.1K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 1, 2026 | Hitchcock Michael | A | $0.00 |
| Apr 1, 2026 | Erdtmann Rainer | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
7 institutional holders with $16.2M total value (13,057,425 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, RENAISSANCE.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 8,813,359 | $10.9M | 67.5% | ADD +33.3% |
| 2 | VANGUARD GROUP INC | 2,968,041 | $3.7M | 22.7% | ADD +36.8% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 478,619 | $593.5K | 3.7% | NEW |
| 4 | TWO SIGMA INVESTMENTS, LP | 423,469 | $525.1K | 3.2% | ADD +61.0% |
| 5 | MORGAN STANLEY | 372,629 | $462.1K | 2.9% | — |
| 6 | BANK OF AMERICA CORP /DE/ | 1,307 | $1.6K | 0.0% | NEAR_EXIT -88.1% |
| 7 | WELLS FARGO & COMPANY/MN | 1 | $1.00 | 0.0% | NEAR_EXIT -99.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 2,170,066 | 2,968,041 | +36.8% | $3.7M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 10,989 | 1,307 | -88.1% | $1.6K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 595,900 | — | $1.2M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 349,647 | 562,968 | +61.0% | $1.1M | 2025-Q3 |
| UBS Group AG | TRIM | 247,663 | 94,532 | -61.8% | $191.0K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 40,924 | 10,989 | -73.1% | $22.2K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 242 | 1 | -99.6% | $3.00 | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 116,549 | 0 | -100.0% | $0.00 | 2025-Q3 |
| FMR LLC | ADD | 5,435,803 | 7,243,912 | +33.3% | $13.0M | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 1,378,064 | 1,879,690 | +36.4% | $3.4M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 472,359 | 349,647 | -26.0% | $629.4K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 181,380 | 116,549 | -35.7% | $209.8K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 69,340 | 40,924 | -41.0% | $73.7K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 13,205 | 242 | -98.2% | $436.00 | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 278,119 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | ADD | 126,039 | 236,876 | +87.9% | $504.5K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 446,851 | 121,916 | -72.7% | $259.7K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 278,145 | 446,851 | +60.7% | $1.7M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 82,300 | 343,732 | +317.7% | $1.3M | 2024-Q4 |
| UBS Group AG | DOUBLED | 34,303 | 126,039 | +267.4% | $489.0K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 8,515 | 12,914 | +51.7% | $50.1K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 208,391 | — | $2.1M | 2024-Q3 |
2 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Hitchcock Michael J.M. | Interim CEO | A | 667,477 | $0.00 | $0.00 |
| Apr 1, 2026 | Erdtmann Rainer M | See Remarks | A | 452,512 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 5.8/10.
NEUTRAL
8-K
4/10
Biomea Fusion reported Q1 2026 net loss of $12.4M ($0.17/share), narrower than the $29.3M loss ($0.8
May 11, 2026
NEUTRAL
PRESS-RELEASE
5/10
Biomea Fusion reported Q1 2026 net loss of $12.4M ($0.17/share), significantly narrower than the $29
May 11, 2026
BULLISH
8-K
7/10
Biomea Fusion reported positive 52-week Phase 2 COVALENT-112 topline data for icovamenib in type 1 d
Apr 28, 2026
BULLISH
8-K
7/10
Biomea Fusion updated its corporate presentation, highlighting positive clinical data from its Phase
Feb 25, 2026
BULLISH
6/10
Biomea Fusion reported positive 52-week Phase 2 data for icovamenib in type 1 diabetes, showing a 52
Apr 27, 2026
BULLISH
7/10
Biomea Fusion announced the first patient dosed in two Phase II trials (COVALENT-211 and COVALENT-21
Mar 31, 2026
NEUTRAL
3/10
Biomea Fusion, Inc. (BMEA) reported its full-year 2025 financial results and provided a business upd
Mar 24, 2026
Current analyst consensus: Strong Buy (85% buy). Based on 13 analysts: 5 strong buy, 6 buy, 1 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$7.29 mean target
+429.9% upside
Strong Buy (1.63)
$4.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $1.38 |
| Target Low | $4.00 |
| Target Mean | $7.29 |
| Target Median | $7.00 |
| Target High | $10.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.63) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.17 | $-0.24 | $-0.10 | 66.4% | -107.9% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.21 | $-0.34 | $-0.10 | 12.6% | -1127.8% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-0.90 | $-1.27 | $-0.48 | 40.7% | +8.0% | 2↑ 0↓ | $0.0B | 0.0% | 5 |
| Next FY 2027-12-31 |
$-1.05 | $-1.40 | $-0.86 | -16.8% | +0.6% | 1↑ 1↓ | $0.0B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.171 | |
| 7d ago | $-0.151 | -0.020 |
| 30d ago | $-0.082 | -0.089 |
| 60d ago | $-0.070 | -0.101 |
| 90d ago | $-0.070 | -0.101 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 5, 2026 | Citizens | INITIATE | — | Market Outperform |
| Apr 28, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 13, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 5 | 6 | 1 | 1 | 0 | 85% | |
| Apr 1, 2026 | 5 | 6 | 1 | 1 | 0 | 85% | |
| Mar 1, 2026 | 5 | 6 | 1 | 1 | 0 | 85% | |
| Feb 1, 2026 | 5 | 6 | 1 | 1 | 0 | 85% | |
| Jan 1, 2026 | 5 | 6 | 1 | 1 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 13, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 13, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
BMEA up 30% - more to come
▲ 1
💬 0
⚡ 0.5
May 19, 2026
short_volume
Short Volume: BMEA — 55.7% short (0.3M / 0.5M)
Short: 292,217 | Exempt: 10 | TRF Vol: 524,496 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
May 14, 2026
Clinical Trial
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
Phase Phase 2 — TERMINATED
May 11, 2026
earnings
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
<p>SAN CARLOS, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinica
May 11, 2026
earnings_calendar
BMEA Q1 2026 Earnings Scheduled — 2026-05-11
May 6, 2026
earnings_calendar
BMEA Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
other
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
<p align="left">SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BME
May 4, 2026
earnings_calendar
BMEA Q1 2026 Earnings Scheduled — 2026-05-04
Apr 27, 2026
fda
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
<p>SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clini
Apr 8, 2026
short_interest
FTD: BMEA — 268,842 shares ($0.5M) failed to deliver
Settlement: 20260408, Price: $1.90, FTD Value: $510,799.8, BIOMEA FUSION INC COM (DE)
Apr 6, 2026
earnings_calendar
BMEA Q4 2025 Earnings After Market Close — 2026-04-06
Mar 31, 2026
fda
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
<p align="center"><em>COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients </em><br><em>COVALENT-212 Phase II enrolling type 2 d
Mar 27, 2026
short_volume
Short Volume: BMEA — 57.0% short (0.5M / 0.9M)
Short: 508,569 | Exempt: 875 | TRF Vol: 892,967 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
earnings
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
<p>SAN CARLOS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clini
Mar 14, 2026
other
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
<p>SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinic